CSF AÎ² 42 levels correlate with amyloid-neuropatholog study

Neurology

60, 652-656

DOI: 10.1212/01.wnl.0000046581.81650.d0

Citation Report

#	Article	IF	Citations
1	CSF markers for incipient Alzheimer's disease. Lancet Neurology, The, 2003, 2, 605-613.	4.9	1,156
2	CSF biomarkers for mild cognitive impairment. Journal of Internal Medicine, 2004, 256, 224-234.	2.7	138
3	Genetic variants ofABCA1 modify Alzheimer disease risk and quantitative traits related to ?-amyloid metabolism. Human Mutation, 2004, 23, 358-367.	1.1	120
4	Cerebrospinal fluid protein biomarkers for Alzheimerâ€™s disease. NeuroRx, 2004, 1, 213-225.	6.0	418
5	APOE promoter, ACE1 and CYP46 polymorphisms and Î²-amyloid in Alzheimerâ€™s disease. NeuroReport, 2004, 15, 95-98.	0.6	37
6	Lithium therapy and cerebrospinal fluid biomarker levels in Alzheimer's disease. Geriatrics and Gerontology International, 2005, 5, 298-300.	0.7	0
7	Cerebrospinal fluid of Alzheimer patients promotes Î²-amyloid fibril formation in vitro. Neurobiology of Disease, 2005, 20, 233-240.	2.1	22
8	Familial Alzheimer disease: Decreases in CSF AÂ42 levels precede cognitive decline. Neurology, 2005, 65, 323-325.	1.5	89
9	Biochemical Markers and Risk Factors of Alzheimers Disease. Current Alzheimer Research, 2005, 2, 47-64.	0.7	64
10	Use of laboratory and imaging investigations in dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, v45-v52.	0.9	11
11	How proteomics reveals potential biomarkers in brain diseases. Expert Review of Proteomics, 2005, 2, 901-913.	1.3	14
12	CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Clinical Neurology and Neurosurgery, 2005, 107, 165-173.	0.6	179
13	Beta-Amlyoid 1â€“42 and Tau-Protein in Cerebrospinal Fluid of Patients with Parkinsonâ€™s Disease Dementia. Dementia and Geriatric Cognitive Disorders, 2006, 22, 200-208.	0.7	114
14	Blood-borne factors inhibit Alzheimer's Î²-amyloid fibril formation in vitro. Experimental Neurology, 2006, 202, 125-132.	2.0	9
15	Neuropsychological and behavioural correlates of CSF biomarkers in dementia. Neurochemistry International, 2006, 48, 286-295.	1.9	61
16	Clinical evaluation as a biomarker for Alzheimer's disease. Journal of Alzheimer's Disease, 2006, 8, 327-337.	1.2	13
18	Cerebrospinal fluid biomarkers for mild cognitive impairment. Aging Health, 2006, 2, 111-121.	0.3	6
19	Associations between white matter lesions, cerebrovascular risk factors, and low CSF AÂ42. Neurology, 2006, 67, 830-833.	1.5	44

#	Article	IF	Citations
20	Laboratory Diagnosis of Dementia. Laboratory Medicine, 2006, 37, 362-365.	0.8	1
22	Diagnosing prodromal Alzheimer's disease: Role of CSF biochemical markers. Mechanisms of Ageing and Development, 2006, 127, 129-132.	2.2	93
23	Early diagnostics and therapeutics for Alzheimerâ€™s disease â€“ how early can we get there?. Expert Review of Neurotherapeutics, 2006, 6, 1293-1306.	1.4	24
24	Cerebrospinal fluid Â-amyloid 1-42 concentration may predict cognitive decline in older women. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 461-464.	0.9	189
25	Age and Apolipoprotein E*4 Allele Effects on Cerebrospinal Fluid Î²-Amyloid 42 in Adults With Normal Cognition. Archives of Neurology, 2006, 63, 936.	4.9	118
26	CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain, 2006, 129, 3035-3041.	3.7	541
27	No association of CSF biomarkers with APOEÂ4, plaque and tangle burden in definite Alzheimer's disease. Brain, 2007, 130, 2320-2326.	3.7	110
28	Prediction of Alzheimerâ€™s Disease Using the CSF AÎ²42/AÎ²40 Ratio in Patients with Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2007, 23, 316-320.	0.7	248
29	CSF AÎ²42, Tau and phosphorylated Tau, APOE É›4 allele and MCI type in progressive MCI. Neurobiology of Aging, 2007, 28, 507-514.	1.5	101
30	Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neuroscience Letters, 2007, 419, 18-22.	1.0	169
31	Aspects of Î²-amyloid as a biomarker for Alzheimerâ€™s disease. Biomarkers in Medicine, 2007, 1, 59-78.	0.6	73
32	Effect of HMG-CoA Reductase Inhibitors on ??-Amyloid Peptide Levels. CNS Drugs, 2007, 21, 449-462.	2.7	53
33	Intra-Individual Stability of CSF Biomarkers for Alzheimer's Disease over Two Years. Journal of Alzheimer's Disease, 2007, 12, 255-260.	1.2	117
34	Extreme cerebrospinal fluid amyloid Î² levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. Annals of Neurology, 2007, 61, 446-453.	2.8	87
35	Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. European Journal of Neurology, 2007, 14, e1-e26.	1.7	499
37	Tauopathies and synucleinopathies: Do cerebrospinal fluid Î²-amyloid peptides reflect disease-specific pathogenesis?. Journal of Neural Transmission, 2007, 114, 919-927.	1.4	33
38	Histologically confirmed amyloid deposition and low CSF AÎ² 42 in a cognitively normal subject. Journal of Neurology, 2007, 254, 970-971.	1.8	1
39	Laboratory biomarkers in Alzheimerâ€™s disease. Current Neurology and Neuroscience Reports, 2007, 7, 381-387.	2.0	9

#	Article	IF	Citations
40	Targeted proteomics in Alzheimerâ€™s disease: focus on amyloid-Î². Expert Review of Proteomics, 2008, 5, 225-237.	1.3	49
41	White matter lesion severity is associated with reduced cognitive performances in patients with normal CSF AÎ²42 levels. Acta Neurologica Scandinavica, 2008, 118, 373-378.	1.0	11
42	Cerebrospinal fluid markers in Creutzfeldt-Jakob disease. Cerebrospinal Fluid Research, 2008, 5, 14.	0.5	38
43	Cerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies. Biological Psychiatry, 2008, 64, 850-855.	0.7	164
44	CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. Neurobiology of Aging, 2008, 29, 669-675.	1.5	103
46	Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2008, 1782, 549-558.	1.8	72
47	Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimer's and Dementia, 2008, 4, 38-48.	0.4	447
48	Do CSF total tau, phosphorylated tau, and Î²-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature. World Journal of Biological Psychiatry, 2008, 9, 172-182.	1.3	142
49	Biomarkers for Alzheimer Disease in Cerebrospinal Fluid, Urine, and Blood. Molecular Diagnosis and Therapy, 2008, 12, 307-320.	1.6	31
50	Biological CSF Markers of Alzheimer's Disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 261-268.	1.0	9
51	Elevated Cerebrospinal Fluid BACE1 Activity in Incipient Alzheimer Disease. Archives of Neurology, 2008, 65, 1102-7.	4.9	193
52	Increased CSF-BACE 1 activity is associated with ApoE-Îµ4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. Brain, 2008, 131, 1252-1258.	3.7	109
53	CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology, 2008, 70, 1827-1835.	1.5	207
54	PET Amyloid Ligand [¹¹C]PIB Uptake and Cerebrospinal Fluid Î²-Amyloid in Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2008, 26, 378-383.	0.7	100
55	Is Plasma Amyloid-β a Reliable Biomarker for Alzheimers Disease?. Recent Patents on CNS Drug Discovery, 2008, 3, 109-111.	0.9	16
56	CSF AÎ²42, Tau and Phosphorylated Tau Correlate with Medial Temporal Lobe Atrophy. Journal of Alzheimer's Disease, 2008, 14, 51-57.	1.2	42
57	Biomarkers in vascular dementia. , 2009, , 77-92.		1
58	Plasma Levels of Amyloid Î²1-42 Are Independent of Neuronal Function in Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 17, 343-348.	1.2	6

#	Article	IF	Citations
59	Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 20324-20329.	3.3	361
60	Progression of Mild Cognitive Impairment to Alzheimer’s Disease: Improved Diagnostic Value of the Combined Use of N200 Latency and β-Amyloid(1–42) Levels. Dementia and Geriatric Cognitive Disorders, 2009, 28, 30-35.	0.7	28
61	Cerebrospinal Fluid Î²-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain. Archives of Neurology, 2009, 66, 382-9.	4.9	747
62	New Perspectives for the Diagnosis of Alzheimers Disease. Recent Patents on CNS Drug Discovery, 2009, 4, 160-181.	0.9	15
63	MRI and CSF biomarkers in normal, MCI, and AD subjects. Neurology, 2009, 73, 294-301.	1.5	357
64	Biomarkers in Relation to Cognitive Reserve in Patients with Mild Cognitive Impairment â€“ Proof of Concept. Dementia and Geriatric Cognitive Disorders, 2009, 27, 194-200.	0.7	29
65	Biomarkers of Alzheimer's disease. Neurobiology of Disease, 2009, 35, 128-140.	2.1	175
66	Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurology, 2009, 9, 63.	0.8	126
67	Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Annals of Neurology, 2010, 67, 308-316.	2.8	160
68	Neurochemical biomarkers in the differential diagnosis of movement disorders. Movement Disorders, 2009, 24, 1411-1426.	2.2	37
69	Cerebrospinal tau, phosphoâ€tau, and betaâ€amyloid and neuropsychological functions in Parkinson's disease. Movement Disorders, 2009, 24, 2203-2210.	2.2	163
70	Beta-Amyloid Deposition and the Aging Brain. Neuropsychology Review, 2009, 19, 436-450.	2.5	156
71	Host and Viral Factors Influencing the Pathogenesis of HIV-Associated Neurocognitive Disorders. Journal of NeuroImmune Pharmacology, 2009, 4, 175-189.	2.1	32
72	Use of CSF biomarkers in Alzheimer's disease clinical trials. Journal of Nutrition, Health and Aging, 2009, 13, 358-361.	1.5	15
73	Association between FDG uptake, CSF biomarkers and cognitive performance in patients with probable Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1090-1100.	3.3	26
74	Clearance mechanisms of Alzheimer's amyloid-Î² peptide: implications for therapeutic design and diagnostic tests. Molecular Psychiatry, 2009, 14, 469-486.	4.1	208
75	CSF Biomarkers. Annals of the New York Academy of Sciences, 2009, 1180, 28-35.	1.8	60
76	Single-step detection of mutant huntingtin in animal and human tissues: A bioassay for Huntingtonâ€™s disease. Analytical Biochemistry, 2009, 395, 8-15.	1.1	115

#	Article	IF	Citations
77	Patients With Alzheimer Disease With Multiple Microbleeds. Stroke, 2009, 40, 3455-3460.	1.0	202
78	Zinc and copper modulate Alzheimer AÎ² levels in human cerebrospinal fluid. Neurobiology of Aging, 2009, 30, 1069-1077.	1.5	126
79	CSF biomarker levels in early and late onset Alzheimer's disease. Neurobiology of Aging, 2009, 30, 1895-1901.	1.5	121
80	No correlation between time-linked plasma and CSF AÎ² levels. Neurochemistry International, 2009, 55, 820-825.	1.9	53
81	Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal Fluid. Biological Psychiatry, 2009, 65, 927-934.	0.7	256
82	Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurology, The, 2009, 8, 619-627.	4.9	542
83	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 18, 413-417.	1.2	122
84	Memory in individuals with mild cognitive impairment in relation to APOE and CSF AÎ²42. International Psychogeriatrics, 2010, 22, 598-606.	0.6	10
85	Cerebrospinal Fluid Tau and Amyloid Î² Proteins Do Not Correlate With Cognitive Functioning in Cognitively Impaired Memory Clinic Patients. CNS Spectrums, 2010, 15, 588-593.	0.7	4
87	Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurology, The, 2010, 9, 119-128.	4.9	3,792
89	Amyloid Î² and APP as biomarkers for Alzheimerâ€™s disease. Experimental Gerontology, 2010, 45, 23-29.	1.2	104
90	Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity. International Journal of Geriatric Psychiatry, 2010, 25, 403-410.	1.3	109
91	Distinct cerebrospinal fluid amyloid Î² peptide signatures in sporadic and PSEN1A431E-associated familial Alzheimer's disease. Molecular Neurodegeneration, 2010, 5, 2.	4.4	79
92	Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nature Reviews Drug Discovery, 2010, 9, 560-574.	21.5	560
93	High Education May Offer Protection Against Tauopathy in Patients with Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2010, 21, 221-228.	1.2	25
94	Cerebrospinal Fluid Analysis Should Be Considered in Patients with Cognitive Problems. International Journal of Alzheimer's Disease, 2010, 2010, 1-4.	1.1	6
95	Pleiotropy in the Presence of Allelic Heterogeneity: Alternative Genetic Models for the Influence of APOE on Serum LDL, CSF Amyloid-Î²42, and Dementia. Journal of Alzheimer's Disease, 2010, 22, 129-134.	1.2	23
96	Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease. International Journal of Alzheimer's Disease, 2010, 2010, 1-5.	1.1	27

#	Article	IF	Citations
97	Differential levels of Â-synuclein, Â-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 608-610.	0.9	135
98	Quantitative structural MRI for early detection of Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2010, 10, 1675-1688.	1.4	57
99	Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain, 2010, 133, 3336-3348.	3.7	455
100	An overview of biomarkers in Alzheimerâ€²s disease. Annals of Indian Academy of Neurology, 2010, 13, 116.	0.2	20
101	Alzheimers Disease and Retinal Neurodegeneration. Current Alzheimer Research, 2010, 7, 3-14.	0.7	143
102	Combination of P300 and CSF β-Amyloid(1-42) Assays May Provide a Potential Tool in the Early Diagnosis of Alzheimers Disease. Current Alzheimer Research, 2010, 7, 295-299.	0.7	26
103	From mild cognitive impairment to prodromal Alzheimer disease: A nosological evolution. European Geriatric Medicine, 2010, 1, 146-154.	1.2	4
104	Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid. Cerebrospinal Fluid Research, 2010, 7, 10.	0.5	51
105	Evaluation of plasma AÎ²40 and AÎ²42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiology of Aging, 2010, 31, 357-367.	1.5	242
106	Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nature Reviews Neurology, 2010, 6, 131-144.	4.9	1,598
107	Brain Atrophy in Healthy Aging Is Related to CSF Levels of AÎ²1-42. Cerebral Cortex, 2010, 20, 2069-2079.	1.6	102
108	Biological markers of amyloid Î²-related mechanisms in Alzheimer's disease. Experimental Neurology, 2010, 223, 334-346.	2.0	145
109	Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses. Alzheimer's and Dementia, 2010, 6, 104-109.	0.4	31
110	Biochemical markers in Alzheimerâ€™s disease clinical trials. Biomarkers in Medicine, 2010, 4, 91-98.	0.6	14
111	BACE1 Activity in Cerebrospinal Fluid and Its Relation to Markers of AD Pathology. Journal of Alzheimer's Disease, 2010, 20, 253-260.	1.2	75
112	Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease. Alzheimer's Research and Therapy, 2010, 2, 32.	3.0	15
113	Use of Biomarkers in Clinical Trials of Alzheimer Disease. Molecular Diagnosis and Therapy, 2011, 15, 313-325.	1.6	20
115	Role of CSF biomarkers in the diagnosis of prodromal Alzheimerâ€™s disease. Biomarkers in Medicine, 2011, 5, 479-484.	0.6	12

#	Article	IF	Citations
116	CSF biomarkers in neurodegenerative diseases. Clinical Chemistry and Laboratory Medicine, 2011, 49, 345-352.	1.4	56
117	Current and Emerging Drug Treatment Options for AlzheimerÊ¼s Disease. Drugs, 2011, 71, 2031-2065.	4.9	196
118	Increased CSF-BACE1 Activity Associated with Decreased Hippocampus Volume in Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 25, 373-381.	1.2	50
119	Cerebrospinal fluid profile of amyloid Î²42 (AÎ²42), hTau and ubiquitin in North Indian Alzheimer's disease patients. Neuroscience Letters, 2011, 487, 134-138.	1.0	27
120	Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends in Neurosciences, 2011, 34, 430-442.	4.2	309
121	Biomarker-based dissection of neurodegenerative diseases. Progress in Neurobiology, 2011, 95, 520-534.	2.8	82
122	Evidence for Ordering of Alzheimer Disease Biomarkers. Archives of Neurology, 2011, 68, 1526.	4.9	195
123	Metabolomic changes in autopsyâ€confirmed Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 309-317.	0.4	132
124	Biomarkers in Alzheimer's disease drug development. Alzheimer's and Dementia, 2011, 7, e13-44.	0.4	104
125	Transforming cerebrospinal fluid AÎ²42 measures into calculated Pittsburgh compound B units of brain AÎ² amyloid. , 2011, 7, 133-141.		85
126	Impact of apolipoprotein É›4-cerebrospinal fluid beta-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment. , 2011, 7, 514-520.		26
127	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's and Dementia, 2011, 7, 386.	0.4	354
128	Cerebrospinal Fluid Tau in Frontotemporal Lobar Degeneration: Clinical, Neuroimaging, and Prognostic Correlates. Journal of Alzheimer's Disease, 2011, 23, 505-512.	1.2	9
129	Alzheimerâ€™s Diseases: Towards Biomarkers for an Early Diagnosis. , 2011, , .		0
130	Clinical practice guideline for dementia by Clinical Research Center for Dementia of South Korea. Journal of the Korean Medical Association, 2011, 54, 861.	0.1	26
131	Biomarkers in Alzheimerâ€™s Disease. Frontiers in Neurology, 2011, 2, 46.	1.1	19
132	Novel AβIsoforms in Alzheimer's Disease - Their Role in Diagnosis and Treatment. Current Pharmaceutical Design, 2011, 17, 2594-2602.	0.9	66
133	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Diagnostic Performance in a Homogeneous Mono-Center Population. Journal of Alzheimer's Disease, 2011, 24, 537-546.	1.2	68

#	Article	IF	Citations
134	Transthyretin and the brain re-visited: Is neuronal synthesis of transthyretin protective in Alzheimer's disease?. Molecular Neurodegeneration, 2011, 6, 79.	4.4	84
135	Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathologica, 2011, 121, 597-609.	3.9	256
136	In vivo demonstration of amyloid burden in posterior cortical atrophy: a case series with PET and CSF findings. Journal of Neurology, 2011, 258, 1841-1851.	1.8	64
137	Occlusal Disharmony Increases Amyloid-Î² in the Rat Hippocampus. NeuroMolecular Medicine, 2011, 13, 197-203.	1.8	27
138	Reduced CSF turnover and decreased ventricular AÎ²42 levels are related. BMC Neuroscience, 2011, 12, 42.	0.8	15
139	Amyloidâ€Î² associated volume loss occurs only in the presence of phosphoâ€tau. Annals of Neurology, 2011, 70, 657-661.	2.8	109
140	Using biomarkers to improve detection of Alzheimerâ€™s disease. Neurodegenerative Disease Management, 2011, 1, 127-139.	1.2	28
141	Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition. Brain, 2011, 134, 1479-1492.	3.7	118
142	Role of amyloid Î²1â€“42 and neuroimaging biomarkers in Alzheimerâ€™s disease. Biomarkers in Medicine, 2011, 5, 411-413.	0.6	13
143	Longitudinal Change of Biomarkers in Cognitive Decline. Archives of Neurology, 2011, 68, 1257.	4.9	152
144	Amyloid Î² (AÎ²) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease. Clinical Chemistry and Laboratory Medicine, 2011, 49, 367-374.	1.4	62
145	Glaucoma and Alzheimerâ€™s disease in the elderly. Aging Health, 2011, 7, 719-733.	0.3	12
146	Challenges in the development of companion diagnostics for neuropsychiatric disorders. Expert Review of Molecular Diagnostics, 2011, 11, 829-837.	1.5	9
147	New Tools for the Study of Alzheimerâ€™s Disease. Neuroscientist, 2011, 17, 592-605.	2.6	12
148	Using Pittsburgh Compound B for In Vivo PET Imaging of Fibrillar Amyloid-Beta. Advances in Pharmacology, 2012, 64, 27-81.	1.2	78
149	All Cognitive Systems but Speed and Visuospatial Functions Reduce the Effect of CSF Pathology on Other Systems. Current Alzheimer Research, 2012, 9, 1043-1049.	0.7	1
150	Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough. Imaging in Medicine, 2012, 4, 343-357.	0.0	12
152	Longitudinal Cerebrospinal Fluid Biomarkers over Four Years in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2012, 30, 767-778.	1.2	76

#	Article	IF	Citations
153	Longitudinal Stability Evaluation of Biomarkers and Their Correlation in Cerebrospinal Fluid and Plasma from Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 32, 939-947.	1.2	9
154	The diagnosis and evaluation of dementia and mild cognitive impairment with emphasis on SPECT perfusion neuroimaging. CNS Spectrums, 2012, 17, 176-206.	0.7	28
155	Development and assessment of sensitive immunoâ€<scp>PCR</scp> assays for the quantification of cerebrospinal fluid threeâ€•and fourâ€repeat tau isoforms in tauopathies. Journal of Neurochemistry, 2012, 123, 396-405.	2.1	64
156	Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimerâ€™s disease. Methods, 2012, 56, 484-493.	1.9	85
158	Plasma Amyloid-Î² Levels and Prognosis in Incident Dementia Cases of the 3-City Study. Journal of Alzheimer's Disease, 2012, 33, 381-391.	1.2	21
159	Fluid Biomarkers in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006221-a006221.	2.9	159
160	Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease. Neurobiology of Aging, 2012, 33, 1599-1608.	1.5	52
161	Conformational Differences between Two Amyloid Î² Oligomers of Similar Size and Dissimilar Toxicity. Journal of Biological Chemistry, 2012, 287, 24765-24773.	1.6	191
162	Clinical use of cerebrospinal fluid biomarkers in Alzheimerâ€™s disease. Biomarkers in Medicine, 2012, 6, 371-376.	0.6	4
163	Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimerâ€™s disease and other neurodegenerative dementias. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 71-77.	1.8	24
164	CSF biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimerâ€™s pathological cascade. Brain Imaging and Behavior, 2012, 6, 599-609.	1.1	46
165	Beta amyloid, tau, neuroimaging, and cognition: sequence modeling of biomarkers for Alzheimerâ€™s Disease. Brain Imaging and Behavior, 2012, 6, 610-620.	1.1	59
166	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: More to Come?. Journal of Alzheimer's Disease, 2012, 33, S361-S369.	1.2	22
167	The Impact of Cerebrospinal Fluid Biomarkers on the Diagnosis of Alzheimerâ€™s Disease. Molecular Diagnosis and Therapy, 2012, 16, 135-141.	1.6	22
168	A Possible Role for CSF Turnover and Choroid Plexus in the Pathogenesis of Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 30, 17-26.	1.2	95
169	-Synuclein as CSF and Blood Biomarker of Dementia with Lewy Bodies. International Journal of Alzheimer's Disease, 2012, 2012, 1-9.	1.1	34
170	Grey Matter and Cognitive Patterns in Cognitive Impaired Subjects Using CSF Biomarker Cut-Offs. Journal of Alzheimer's Disease, 2012, 29, 741-749.	1.2	1
172	Evidence for an effect of single nucleotide polymorphisms in SORL1 on cerebrospinal fluid markers of Alzheimerâ€™s disease. Future Neurology, 2012, 7, 123-126.	0.9	0

#	Article	IF	Citations
173	Alzheimer Disease: New Concepts on Its Neurobiology and the Clinical Role Imaging Will Play. Radiology, 2012, 263, 344-361.	3.6	192
174	CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology, 2012, 78, 1568-1575.	1.5	208
175	New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. British Journal of Clinical Pharmacology, 2012, 73, 504-517.	1.1	253
176	The value of cerebrospinal fluid biomarkers for the differential diagnosis of dementia. Neurodegenerative Disease Management, 2012, 2, 211-219.	1.2	1
177	CSF Biomarkers for Amyloid and Tau Pathology in Alzheimer's Disease. Journal of Molecular Neuroscience, 2012, 47, 1-14.	1.1	56
178	Measurement of AÎ²1â€“42 in cerebrospinal fluid is influenced by matrix effects. Journal of Neurochemistry, 2012, 120, 325-333.	2.1	38
179	Hippocampal Subregions are Differentially Affected in the Progression to Alzheimer's Disease. Anatomical Record, 2012, 295, 132-140.	0.8	34
180	Neuroimaging Results Impose New Views on Alzheimerâ€™s Diseaseâ€”the Role of Amyloid Revised. Molecular Neurobiology, 2012, 45, 153-172.	1.9	44
181	The development of effective biomarkers for Alzheimer's disease: a review. International Journal of Geriatric Psychiatry, 2013, 28, 331-340.	1.3	46
182	Fluid biomarkers in Alzheimerâ€™s disease â€“ current concepts. Molecular Neurodegeneration, 2013, 8, 20.	4.4	180
183	Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement. Journal of Nutrition, Health and Aging, 2013, 17, 54-63.	1.5	28
184	Latin American Experience with Alzheimer's Disease Cerebrospinal Fluid Biomarkers. Journal of the American Geriatrics Society, 2013, 61, 1229-1231.	1.3	3
185	Supporting evidence for using biomarkers in the diagnosis of MCI due to AD. Journal of Neurology, 2013, 260, 640-650.	1.8	50
186	Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease. Annals of Neurology, 2013, 74, 655-668.	2.8	171
187	Emerging Biomarkers in Cognition. Clinics in Geriatric Medicine, 2013, 29, 809-828.	1.0	13
188	Exacerbated CSF abnormalities in younger patients with Alzheimer's disease. Neurobiology of Disease, 2013, 54, 486-491.	2.1	14
189	Biomarker Modeling of Alzheimerâ€™s Disease. Neuron, 2013, 80, 1347-1358.	3.8	773
190	Comparing positron emission tomography imaging and cerebrospinal fluid measurements of Î²â€amyloid. Annals of Neurology, 2013, 74, 826-836.	2.8	320

#	Article	IF	Citations
191	Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurology, The, 2013, 12, 207-216.	4.9	3,378
192	TraitÃ© sur la maladie dâ€™Alzheimer. , 2013, , .		0
193	Alzheimer disease: From biomarkers to diagnosis. Revue Neurologique, 2013, 169, 744-751.	0.6	22
194	Clinical indications for analysis of Alzheimer's disease CSF biomarkers. Revue Neurologique, 2013, 169, 709-714.	0.6	19
195	Visual ratings of atrophy in MCI: prediction of conversion and relationship with CSF biomarkers. Neurobiology of Aging, 2013, 34, 73-82.	1.5	41
196	Cerebrospinal fluid biomarkers in neurological diseases inÂchildren. European Journal of Paediatric Neurology, 2013, 17, 7-13.	0.7	18
197	GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimerâ€™s Disease. Neuron, 2013, 78, 256-268.	3.8	344
198	Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-Î² changes occur before increases of tau in cerebrospinal fluid. Acta Neuropathologica, 2013, 126, 631-641.	3.9	125
199	Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections. Journal of Neurology, 2013, 260, 620-626.	1.8	87
200	Brain Changes in Older Adults at Very Low Risk for Alzheimer's Disease. Journal of Neuroscience, 2013, 33, 8237-8242.	1.7	184
201	Correlations of CSF tau and amyloid levels with Alzheimer pathology in neuropathologically verified dementia with Lewy bodies. International Journal of Geriatric Psychiatry, 2013, 28, 738-744.	1.3	22
202	New diagnostic concepts in Alzheimer's disease. Advances in Psychiatric Treatment, 2013, 19, 242-249.	0.6	3
203	Cerebrospinal fluid biomarkers for pathological processes in Alzheimer's disease. Current Opinion in Psychiatry, 2013, 26, 276-282.	3.1	20
204	Amyloid-Î² Peptides and Tau Protein as Biomarkers in Cerebrospinal and Interstitial Fluid Following Traumatic Brain Injury: A Review of Experimental and Clinical Studies. Frontiers in Neurology, 2013, 4, 79.	1.1	99
205	Association of 1H-MR Spectroscopy and Cerebrospinal Fluid Biomarkers in Alzheimer's Disease: Diverging Behavior at Three Different Brain Regions. Journal of Alzheimer's Disease, 2013, 36, 155-163.	1.2	35
206	CSF protein biomarkers predicting longitudinal reduction of CSF Î²-amyloid42 in cognitively healthy elders. Translational Psychiatry, 2013, 3, e293-e293.	2.4	51
207	A Blood Gene Expression Marker of Early Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 33, 737-753.	1.2	91
208	The Role of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease Diagnosis. Where are we Now?. Recent Patents on CNS Drug Discovery, 2013, 8, 70-78.	0.9	4

#	Article	IF	Citations
209	Amyloid Pathology Influences AÎ²1-42 Cerebrospinal Fluid Levels in Dementia with Lewy Bodies. Journal of Alzheimer's Disease, 2013, 35, 137-146.	1.2	45
210	Frontal presentation of Alzheimer's disease: A series of patients with biological evidence by CSF biomarkers. Dementia E Neuropsychologia, 2013, 7, 66-74.	0.3	29
211	BrainAGE in Mild Cognitive Impaired Patients: Predicting the Conversion to Alzheimerâ€™s Disease. PLoS ONE, 2013, 8, e67346.	1.1	412
212	Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimerâ€™s Disease. PLoS ONE, 2013, 8, e76523.	1.1	173
213	CSF Biomarkers of Alzheimerâ€™s Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design. Advances in Geriatrics, 2014, 2014, 1-14.	1.6	15
214	Genetic variation modifies risk for neurodegeneration based on biomarker status. Frontiers in Aging Neuroscience, 2014, 6, 183.	1.7	18
215	Biological markers of Alzheimer?s disease. Arquivos De Neuro-Psiquiatria, 2014, 72, 227-231.	0.3	18
216	Cerebrospinal Fluid Biomarkers Can Play a Pivotal Role in the Diagnostic Work Up of Primary Progressive Aphasia. Journal of Alzheimer's Disease, 2014, 43, 1429-1440.	1.2	21
217	Clearing the amyloid in Alzheimer's: progress towards earlier diagnosis and effective treatments â€“ an update for clinicians. Neurodegenerative Disease Management, 2014, 4, 363-378.	1.2	20
218	Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimerâ€™s Disease. Science Translational Medicine, 2014, 6, 226ra30.	5.8	320
219	Metabolite and Peptide Levels in Plasma and CSF Differentiating Healthy Controls from Patients with Newly Diagnosed Parkinson's Disease. Journal of Parkinson's Disease, 2014, 4, 549-560.	1.5	99
220	Emerging Î²-Amyloid Pathology and Accelerated Cortical Atrophy. JAMA Neurology, 2014, 71, 725.	4.5	51
222	Biomarkers in Amyloid-Î² Immunotherapy Trials in Alzheimerâ€™s Disease. Neuropsychopharmacology, 2014, 39, 189-201.	2.8	66
223	Impact of cerebro-spinal fluid biomarkers of Alzheimerâ€™s disease in clinical practice: a multicentric study. Journal of Neurology, 2014, 261, 144-151.	1.8	56
224	Neurodegenerative Diseases. , 2014, , .		3
225	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurology, The, 2014, 13, 614-629.	4.9	2,657
227	Genomeâ€wide association study of the rate of cognitive decline in Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 45-52.	0.4	147
228	CSF AÎ²1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease. , 2014, 10, 381-392.		64

#	Article	IF	Citations
229	CSF AÎ² ₄₂ predicts early-onset dementia in Parkinson disease. Neurology, 2014, 82, 1784-1790.	1.5	135
230	Assessment of CSF AÎ²42 as an aid to discriminating Alzheimer's disease from other dementias and mild cognitive impairment: A meta-analysis of 50 studies. Journal of the Neurological Sciences, 2014, 345, 26-36.	0.3	40
231	CSF in Alzheimer's Disease. Advances in Clinical Chemistry, 2014, 65, 143-172.	1.8	19
232	The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimer's and Dementia, 2014, 10, 808-817.	0.4	163
233	A Method for Evaluating the Level of Soluble Î²â€Amyloid_(1â€“40/1â€“42) in Alzheimerâ€™s Disease Based on the Binding of Gelsolin to Î²â€Amyloid Peptides. Angewandte Chemie - International Edition, 2014, 53, 12832-12835.	7.2	63
234	Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology. Alzheimer's and Dementia, 2014, 10, 724-734.	0.4	182
235	Progress Update: Fluid and Imaging Biomarkers in Alzheimerâ€™s Disease. Biological Psychiatry, 2014, 75, 520-526.	0.7	22
236	Post-Translational Modifications in Alzheimer's Disease and the Potential for New Biomarkers. Journal of Alzheimer's Disease, 2014, 41, 345-364.	1.2	22
237	Mercury-induced amyloid-beta (AÎ²) accumulation in the brain is mediated by disruption of AÎ² transport. Journal of Toxicological Sciences, 2014, 39, 625-635.	0.7	27
238	Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A Multicenter Study in Spain. Journal of Alzheimer's Disease, 2014, 39, 719-726.	1.2	53
239	A Method for Evaluating the Level of Soluble Î²â€Amyloid_(1â€“40/1â€“42) in Alzheimerâ€™s Disease Based on the Binding of Gelsolin to Î²â€Amyloid Peptides. Angewandte Chemie, 2014, 126, 13046-13049.	1.6	20
240	Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease. Annals of Clinical and Translational Neurology, 2015, 2, 534-547.	1.7	32
241	Alzheimer's disease. Nature Reviews Disease Primers, 2015, 1, 15056.	18.1	1,210
242	Common Variants in PLD3 and Correlation to Amyloid-Related Phenotypes in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 46, 491-495.	1.2	19
243	Biomarkers in Sporadic and Familial Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 47, 291-317.	1.2	75
244	Can agrin cerebrospinal fluid concentration be used as an early biomarker for Alzheimer's disease?. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 75-80.	1.2	4
245	Mirror Image of the Amyloid-Î² Species in Cerebrospinal Fluid and Cerebral Amyloid inÂAlzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 47, 877-881.	1.2	9
246	In-vivo brain neuroimaging provides a gateway for integrating biological and clinical biomarkers of Alzheimer's disease. Current Opinion in Neurology, 2015, 28, 351-357.	1.8	14

#	Article	IF	Citations
247	Cognitive reserve and Aβ1-42 in mild cognitive impairment (Argentina-Alzheimer’s) Tj ETQq0 0 0 rgBT /Overlock 1	1.0	13
248	A Consensus in Korea Regarding a Protocol to Reduce Preanalytical Sources of Variability in the Measurement of the Cerebrospinal Fluid Biomarkers of Alzheimer's Disease. Journal of Clinical		

#	Article	IF	Citations
265	Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer's disease. Neurobiology of Aging, 2015, 36, 2018-2023.	1.5	75
266	Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 Î²-Amyloid Measures Across the Spectrum of Alzheimer Disease. JAMA Neurology, 2015, 72, 571.	4.5	87
267	Mild Cognitive Impairment Due to Alzheimer Disease is Less Likely Under the Age of 65. Alzheimer Disease and Associated Disorders, 2015, 29, 26-31.	0.6	6
268	CSF biomarkers for the differential diagnosis of Alzheimer's disease: A largeâ€scale international multicenter study. Alzheimer's and Dementia, 2015, 11, 1306-1315.	0.4	104
269	Amyloid biomarkers in Alzheimer's disease. Trends in Pharmacological Sciences, 2015, 36, 297-309.	4.0	404
270	Dissecting IWG-2 typical and atypical Alzheimerâ€™s disease: insights from cerebrospinal fluid analysis. Journal of Neurology, 2015, 262, 2722-2730.	1.8	39
271	Relationship between cerebrospinal fluid biomarkers of Alzheimer's disease and cognition in cognitively normal older adults. Neuropsychologia, 2015, 78, 63-72.	0.7	35
272	Visualization of regional tau deposits using 3H-THK5117 in Alzheimer brain tissue. Acta Neuropathologica Communications, 2015, 3, 40.	2.4	58
273	Different cerebrospinal fluid levels of <scp>A</scp>lzheimerâ€type biomarker AÎ²42 between general paresis and asymptomatic neurosyphilis. European Journal of Neurology, 2015, 22, 853-858.	1.7	8
274	Identifying amyloid pathologyâ€“related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 339-348.	1.2	35
275	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nature Reviews Neurology, 2015, 11, 41-55.	4.9	144
276	Age-associated evolution of plasmatic amyloid in mouse lemur primates: relationship with intracellular amyloid deposition. Neurobiology of Aging, 2015, 36, 149-156.	1.5	15
277	Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 58-69.	0.4	352
278	Interconnection Between Brain and Retinal Neurodegenerations. Molecular Neurobiology, 2015, 51, 885-892.	1.9	47
279	Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's		

#	Article	IF	Citations
283	The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimerâ€™s Disease: Shortcomings in Prodromal Diagnosis. Journal of Alzheimer's Disease, 2016, 53, 373-392.	1.2	7
284	Spatial Navigation in Preclinical Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 52, 77-90.	1.2	156
285	Cerebrospinal Fluid Biomarkers for Alzheimerâ€™s Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team. Journal of Alzheimer's Disease, 2016, 55, 19-35.	1.2	35
286	Cerebrospinal Fluid Biomarkers and Reserve Variables as Predictors of Future â€œNon-Cognitiveâ€• Outcomes of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 52, 1055-1064.	1.2	8
287	Preclinical Amyloid-Î² and Axonal Degeneration Pathology in Delirium. Journal of Alzheimer's Disease, 2016, 55, 371-379.	1.2	35
288	Molecular and cellular pathophysiology of preclinical Alzheimerâ€™s disease. Behavioural Brain Research, 2016, 311, 54-69.	1.2	99
290	Cerebrospinal Fluid Biomarkers in Alzheimerâ€™s Disease. Methods in Pharmacology and Toxicology, 2016, , 153-179.	0.1	0
291	Diagnostic de la maladie dâ€™AlzheimerÂ: apport de lâ€™imagerie au florbÃ©tapir et autres radiopharmaceutiques de la plaque amyloÃ¯de. Medecine Nucleaire, 2016, 40, 364-381.	0.2	2
292	Epilepsy, amyloid-Î², and D1 dopamine receptors: a possible pathogenetic link?. Neurobiology of Aging, 2016, 48, 161-171.	1.5	71
293	Alzheimerâ€™s Disease Cerebrospinal Fluid (CSF) Biomarkers. , 2016, , 139-180.		4
294	Biochemical and Radiological Markers ofÂAlzheimerâ€™s Disease Progression. Journal of Alzheimer's Disease, 2016, 50, 623-644.	1.2	3
295	Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study. Alzheimer's Research and Therapy, 2016, 8, 27.	3.0	18
296	Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseasesâ€”From pathophysiology to clinical practice. Movement Disorders, 2016, 31, 836-847.	2.2	54
297	Fluid Biomarkers and Diagnostics. , 2016, , 565-587.		0
298	Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2016, 11, 3.	4.4	236
299	Advances in the Simulation of Protein Aggregation at the Atomistic Scale. Journal of Physical Chemistry B, 2016, 120, 2991-2999.	1.2	102
300	<scp>CSF</scp> AÎ²42/AÎ²40 and AÎ²42/AÎ²38 ratios: better diagnostic markers of Alzheimer disease. Annals of Clinical and Translational Neurology, 2016, 3, 154-165.	1.7	329
301	Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders. Journal of Neurochemistry, 2016, 139, 290-317.	2.1	58

#	Article	IF	Citations
302	CSF biomarkers in neurodegenerative and vascular dementias. Progress in Neurobiology, 2016, 138-140, 36-53.	2.8	34
303	Neuroimaging biomarkers in Alzheimerâ€™s disease and other dementias. Ageing Research Reviews, 2016, 30, 4-16.	5.0	32
304	Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation ofÂÎ²â€amyloid (1â€“42) in human cerebrospinal fluid. Alzheimer's and Dementia, 2016, 12, 517-526.	0.4	254
305	Assessing the commutability of reference material formats for the harmonization of amyloid-Î² measurements. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1177-1191.	1.4	49
306	CSF Î²-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease. Journal of Molecular Neuroscience, 2016, 58, 88-92.	1.1	89
307	CSF AÎ²1â€“42 â€“ an excellent but complicated Alzheimer's biomarker â€“ a route to standardisation. Clinica Chimica Acta, 2017, 467, 27-33.	0.5	104
308	Opposing effects of progranulin deficiency on amyloid and tau pathologies via microglial TYROBP network. Acta Neuropathologica, 2017, 133, 785-807.	3.9	67
309	Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration. Translational Psychiatry, 2017, 7, e995-e995.	2.4	56
310	Selecting AÎ² isoforms for an Alzheimer's disease cerebrospinal fluid biomarker panel. Biomarkers in Medicine, 2017, 11, 169-178.	0.6	11
311	Prion-specific and surrogate CSF biomarkers in Creutzfeldt-Jakob disease: diagnostic accuracy in relation to molecular subtypes and analysis of neuropathological correlates of p-tau and AÎ²42 levels. Acta Neuropathologica, 2017, 133, 559-578.	3.9	129
312	Relationship between cytokine levels in the cerebrospinal fluid and 11Câ€Pittsburgh compound B retention in patients with mild cognitive impairment. Geriatrics and Gerontology International, 2017, 17, 1907-1913.	0.7	5
313	BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimerâ€™s Disease Markers in Elderly Healthy Participants. Journal of Alzheimer's Disease, 2017, 56, 1437-1449.	1.2	28
314	Mitochondrial transcription factor A (TFAM) rs1937 and AP endonuclease 1 (APE1) rs1130409 alleles are associated with reduced cognitive performance. Neuroscience Letters, 2017, 645, 46-52.	1.0	13
315	Multiplexing Biomarker Methods, Proteomics and Considerations for Alzheimerâ€™s Disease. Advances in Experimental Medicine and Biology, 2017, 974, 21-48.	0.8	25
316	Low normal cerebrospinal fluid AÎ²42 levels predict clinical progression in nondemented subjects. Annals of Neurology, 2017, 81, 749-753.	2.8	20
317	Clinical validity of cerebrospinal fluid AÎ²42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 196-213.	1.5	100
318	Binding Sites for Amyloid-Î² Oligomers and Synaptic Toxicity. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a024075.	2.9	76
319	Proteomic studies of cerebrospinal fluid biomarkers of Alzheimerâ€™s disease: an update. Expert Review of Proteomics, 2017, 14, 1007-1020.	1.3	21

#	Article	IF	Citations
320	Cerebrospinal Fluid Amyloid-Î² 42, Total Tau and Phosphorylated Tau are Low in Patients with Normal Pressure Hydrocephalus: Analogies and Differences with Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 60, 183-200.	1.2	31
321	Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities. Journal of Neuroscience, 2017, 37, 12263-12271.	1.7	44
322	Implications of peptide assemblies in amyloid diseases. Chemical Society Reviews, 2017, 46, 6492-6531.	18.7	262
323	Cerebrospinal Fluid Biomarkers of Alzheimerâ€™s Disease Correlate With Electroencephalography Parameters Assessed by Exact Low-Resolution Electromagnetic Tomography (eLORETA). Clinical EEG and Neuroscience, 2017, 48, 338-347.	0.9	11
324	AÎ² vaccination in combination with behavioral enrichment in aged beagles: effects on cognition, AÎ², and microhemorrhages. Neurobiology of Aging, 2017, 49, 86-99.	1.5	20
325	Low Florbetapir PET Uptake and Normal AÎ²1-42 Cerebrospinal Fluid in an APP Ala713Thr Mutation Carrier. Journal of Alzheimer's Disease, 2017, 57, 697-703.	1.2	5
326	Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment. JAMA Neurology, 2017, 74, 1492.	4.5	97
327	Cerebrospinal Fluid Biomarkers in Alzheimerâ€™s Diseaseâ€”From Brain Starch to Bench and Bedside. Diagnostics, 2017, 7, 42.	1.3	19
328	Multicenter Analytical Validation of AÎ²40 Immunoassays. Frontiers in Neurology, 2017, 8, 310.	1.1	10
329	Current concepts and controversies in the pathogenesis of Parkinsonâ€™s disease dementia and Dementia with Lewy Bodies. F1000Research, 2017, 6, 1604.	0.8	35
330	Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers. Alzheimer's and Dementia, 2018, 14, 858-868.	0.4	103
331	Biomarkers for Preclinical Alzheimerâ€™s Disease. Neuromethods, 2018, , .	0.2	5
332	Neurodegenerative disease biomarkers AÎ²_{1â€“40}, AÎ²_{1â€“42}, tau, and pâ€tau₁₈₁ in the vervet monkey cerebrospinal fluid: RelationÂto normal aging, genetic influences, and cerebral amyloid angiopathy. Brain and Behavior, 2018, 8, e00903.	1.0	45
333	Low Cerebrospinal Fluid AÎ²42 and AÎ²40 are Related to White Matter Lesions in Cognitively Normal Elderly. Journal of Alzheimer's Disease, 2018, 62, 1877-1886.	1.2	13
334	The Rationale Behind the New Alzheimerâ€™s Disease Conceptualization: Lessons Learned During the Last Decades. Journal of Alzheimer's Disease, 2018, 62, 1067-1077.	1.2	19
335	Subtle Cognitive Impairment and Alzheimerâ€™s Disease-Type Pathological Changes in Cerebrospinal Fluid are Common Among Neurologically Healthy Subjects. Journal of Alzheimer's Disease, 2018, 62, 165-174.	1.2	9
336	AF710B, an M1/sigmaâ€1 receptor agonist with longâ€lasting diseaseâ€modifying properties in a transgenic rat model of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 811-823.	0.4	39
337	Cerebral changes and disrupted gray matter cortical networks in asymptomatic older adults at risk for Alzheimer's disease. Neurobiology of Aging, 2018, 64, 58-67.	1.5	8

#	Article	IF	Citations
338	Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to. Experimental Gerontology, 2018, 107, 169-177.	1.2	36
339	Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimerâ€™s Disease Diagnosis. Journal of Alzheimer's Disease, 2018, 62, 1199-1209.	1.2	69
340	Fluid Biomarkers in Alzheimerâ€™s Disease and Frontotemporal Dementia. , 2018, , 221-252.		1
341	Mild Cognitive Impairment in Parkinsonâ€™s Diseaseâ€"What Is It?. Current Neurology and Neuroscience Reports, 2018, 18, 17.	2.0	57
342	Biomarkers for Alzheimer Disease: Classical and Novel Candidatesâ€™ Review. Neuroscience, 2018, 370, 181-190.	1.1	74
343	Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-Î² 1â€“42 Analysis Results. Clinical Chemistry, 2018, 64, 576-585.	1.5	126
344	Cerebrospinal fluid in the dementias. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 146, 85-97.	1.0	9
345	Wnt signaling loss accelerates the appearance of neuropathological hallmarks of Alzheimer's disease in J20â€<scp>APP</scp> transgenic and wildâ€type mice. Journal of Neurochemistry, 2018, 144, 443-465.	2.1	66
346	Dementia with Lewy bodies and Parkinsonâ€™s disease-dementia: current concepts and controversies. Journal of Neural Transmission, 2018, 125, 615-650.	1.4	200
347	Prognostic value of amyloid PET scan in normal pressure hydrocephalus. Journal of Neurology, 2018, 265, 63-73.	1.8	28
348	Antemortem CSF AÎ²42/AÎ²40 ratio predicts Alzheimer's disease pathology better than AÎ²42 in rapidly progressive dementias. Annals of Clinical and Translational Neurology, 2019, 6, 263-273.	1.7	31
349	miRNAs as biofluid markers for diagnostics of Alzheimerâ€™s disease: recent status andÂperspectives. General Physiology and Biophysics, 2018, 37, 495-514.	0.4	2
350	Evaluation of Matrix Metalloproteinase-2 (MMP-2) and -9 (MMP-9) and Their Tissue Inhibitors (TIMP-1) Tj ETQq0 0 0 rgBT /Overlock 10 T 2018, 66, 1265-1273.	1.2	16
351	Current state of Alzheimerâ€™s fluid biomarkers. Acta Neuropathologica, 2018, 136, 821-853.	3.9	370
352	Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1505-1521.	0.4	163
353	CSF AÎ²1â€“42 level is associated with cognitive decline in early Parkinsonâ€™s disease with rapid eye movement sleep behavior disorder. Translational Neurodegeneration, 2018, 7, 22.	3.6	12
354	Clinical Experience with Cerebrospinal Fluid AÎ²42, Total and Phosphorylated Tau in the Evaluation of 1,016 Individuals for Suspected Dementia. Journal of Alzheimer's Disease, 2018, 65, 1417-1425.	1.2	23
355	The Effect of Dexmedetomidine on Cognitive Function and Protein Expression of AÎ², p-Tau, and PSD95 after Extracorporeal Circulation Operation in Aged Rats. BioMed Research International, 2018, 2018, 1-8.	0.9	14

#	Article	IF	Citations
356	Biomarker for Alzheimer's Disease. , 2018, , 333-349.		1
357	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. Alzheimer's and Dementia, 2018, 14, 1313-1333.	0.4	87
358	Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimerâ€™s disease and vascular dementia. Alzheimer's Research and Therapy, 2018, 10, 58.	3.0	21
359	Biomarkers for Alzheimer's disease: current status and prospects for the future. Journal of Internal Medicine, 2018, 284, 643-663.	2.7	550
360	Imaging Biomarkers of Neurodegeneration in Alzheimerâ€™s Disease: Distinct Contributions of Cortical MRI Atrophy and FDG-PET Hypometabolism. Journal of Alzheimer's Disease, 2018, 65, 1147-1157.	1.2	17
361	Biomarkers in Alzheimerâ€™s, Frontotemporal, Lewy Body, and Vascular Dementias. Focus (American) Tj ETQq1 1 0.784314 rgBT /Ov	0.4	6
362	Concordance between the assessment of AÎ²42, Tâ€tau, and Pâ€T181â€tau in peripheral blood neuronalâ€derived exosomes and cerebrospinal fluid. Alzheimer's and Dementia, 2019, 15, 1071-1080.	0.4	230
363	Amyloid-Î² peptides in cerebrospinal fluid of patients with dementia with Lewy bodies. Alzheimer's Research and Therapy, 2019, 11, 83.	3.0	23
364	EEG time signature in AlzheimerÂ´s disease: Functional brain networks falling apart. NeuroImage: Clinical, 2019, 24, 102046.	1.4	43
365	AD molecular: PET amyloid imaging across the Alzheimer's disease spectrum: From disease mechanisms to prevention. Progress in Molecular Biology and Translational Science, 2019, 165, 63-106.	0.9	10
366	Viewpoint on the role of tissue maintenance in ageing: focus on biomarkers of bone, cartilage, muscle, and brain tissue maintenance. Ageing Research Reviews, 2019, 56, 100964.	5.0	8
367	[11C]PIB PET Is Associated with the Brain Biopsy Amyloid-Î² Load in Subjects Examined for Normal Pressure Hydrocephalus. Journal of Alzheimer's Disease, 2019, 67, 1343-1351.	1.2	13
368	Carnosine Prevents AÎ²-Induced Oxidative Stress and Inflammation in Microglial Cells: A Key Role of TGF-Î²1. Cells, 2019, 8, 64.	1.8	87
369	Reply to â€œobstructive sleep apnea treatment and amyloidâ€Î² in cerebrospinal fluidâ€. Annals of Neurology, 2019, 85, 460-461.	2.8	0
370	Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naÃ¯ve Parkinsonâ€™s disease. BMC Neurology, 2019, 19, 113.	0.8	11
371	Oral Immunization with Soybean Storage Protein Containing Amyloid-Î² 4â€“10 Prevents Spatial Learning Decline. Journal of Alzheimer's Disease, 2019, 70, 487-503.	1.2	4
372	Diagnosis of Alzheimerâ€™s disease utilizing amyloid and tau as fluid biomarkers. Experimental and Molecular Medicine, 2019, 51, 1-10.	3.2	150
373	Frontotemporal dementia is the leading cause of â€œtrueâ€•Aâ€™/T+ profiles defined with AÎ²_{42/40} ratio. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 161-169.	1.2	8

#	Article	IF	Citations
374	Clinical relevance of acute cerebral microinfarcts in vascular cognitive impairment. Neurology, 2019, 92, e1558-e1566.	1.5	24
375	Cerebrospinal Fluid Spermidine, Glutamine and Putrescine Predict Postoperative Delirium Following Elective Orthopaedic Surgery. Scientific Reports, 2019, 9, 4191.	1.6	17
376	Association of Cognitive Function with Amyloid-Î² and Tau Proteins in the Vitreous Humor. Journal of Alzheimer's Disease, 2019, 68, 1429-1438.	1.2	22
377	Search for biomarkers of Alzheimerâ€˜s disease: Recent insights, current challenges and future prospects. Clinical Biochemistry, 2019, 72, 39-51.	0.8	17
378	Comparison between amyloid-PET and CSF amyloid-Î² biomarkers in a clinical cohort with memory deficits. Clinica Chimica Acta, 2019, 492, 62-68.	0.5	20
379	Pyroglutamation of amyloid-Î²x-42 (AÎ²x-42) followed by AÎ²1â€“40 deposition underlies plaque polymorphism in progressing Alzheimerâ€™s disease pathology. Journal of Biological Chemistry, 2019, 294, 6719-6732.	1.6	49
380	Investigating the Association Between Verbal Forgetting and Pathological Markers of Alzheimerâ€™s and Lewy Body Diseases. Journal of Alzheimer's Disease, 2019, 70, 877-887.	1.2	0
381	Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings. Progress in Molecular Biology and Translational Science, 2019, 168, 3-23.	0.9	28
382	PET and CSF amyloid-Î² status are differently predicted by patient features: information from discordant cases. Alzheimer's Research and Therapy, 2019, 11, 100.	3.0	21
383	The relationship between CSF biomarkers and cerebral metabolism in early-onset Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 324-333.	3.3	6
384	Pupillary light reaction in preclinical Alzheimerâ€™s disease subjects compared with normal ageing controls. British Journal of Ophthalmology, 2019, 103, 971-975.	2.1	21
385	Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease. Molecular and Cellular Neurosciences, 2019, 97, 3-17.	1.0	82
386	Association of PTHrP levels in CSF with Alzheimerâ€™s disease biomarkers. Clinical Mass Spectrometry, 2019, 14, 124-129.	1.9	5
387	Hypertension and obesity moderate the relationship between Î²â€amyloid and cognitive decline in midlife. Alzheimer's and Dementia, 2019, 15, 418-428.	0.4	38
388	Fluidâ€based proteomics targeted on pathophysiological processes and pathologies in neurodegenerative diseases. Journal of Neurochemistry, 2019, 151, 417-434.	2.1	15
389	Why Is Amyloid-Î² PET Requested After Performing CSF Biomarkers?. Journal of Alzheimer's Disease, 2020, 73, 559-569.	1.2	8
390	Endocytosis Is a Key Mode of Interaction between Extracellular Î²-Amyloid and the Cell Membrane. Biophysical Journal, 2020, 119, 1078-1090.	0.2	7
391	Amyloidâ€Î² PET and CSF in an autopsyâ€confirmed cohort. Annals of Clinical and Translational Neurology, 2020, 7, 2150-2160.	1.7	17

#	Article	IF	Citations
392	Bridging the Gap Between Fluid Biomarkers for Alzheimerâ€™s Disease, Model Systems, and Patients. Frontiers in Aging Neuroscience, 2020, 12, 272.	1.7	17
393	Fluid Candidate Biomarkers for Alzheimerâ€™s Disease: A Precision Medicine Approach. Journal of Personalized Medicine, 2020, 10, 221.	1.1	20
394	First amyloid Î²1â€42 certified reference material for reâ€calibrating commercial immunoassays. Alzheimer's and Dementia, 2020, 16, 1493-1503.	0.4	42
395	Dynamic Blood Concentrations of AÎ²1â€“40 and AÎ²1â€“42 in Alzheimerâ€™s Disease. Frontiers in Cell and Developmental Biology, 2020, 8, 768.	1.8	14
396	Anterolateral entorhinal cortex thickness as a new biomarker for early detection of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12068.	1.2	16
397	The pathway to secondary prevention of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12069.	1.8	5
398	Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12097.	1.2	5
399	Infusion of blood from mice displaying cerebral amyloidosis accelerates amyloid pathology in animal models of Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2020, 8, 213.	2.4	16
400	APOE2: protective mechanism and therapeutic implications for Alzheimerâ€™s disease. Molecular Neurodegeneration, 2020, 15, 63.	4.4	110
401	Contributions of Molecular and Optical Techniques to the Clinical Diagnosis of Alzheimerâ€™s Disease. Brain Sciences, 2020, 10, 815.	1.1	6
402	Optical coherence tomography reveals light-dependent retinal responses in Alzheimerâ€™s disease. NeuroImage, 2020, 219, 117022.	2.1	11
403	Earliest amyloid and tau deposition modulate the influence of limbic networks during closed-loop hippocampal downregulation. Brain, 2020, 143, 976-992.	3.7	16
404	Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LCâ€“MS/MS Reference Method. Clinical Chemistry, 2020, 66, 587-597.	1.5	15
405	Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases courseâ€”a joint PhD student course at University College London and University of Gothenburg. Alzheimer's Research and Therapy, 2020, 12, 20.	3.0	32
406	Biomarker profiling beyond amyloid and tau: cerebrospinal fluid markers, hippocampal atrophy, and memory change in cognitively unimpaired older adults. Neurobiology of Aging, 2020, 93, 1-15.	1.5	11
407	Urine dicarboxylic acids change in pre-symptomatic Alzheimerâ€™s disease and reflect loss of energy capacity and hippocampal volume. PLoS ONE, 2020, 15, e0231765.	1.1	12
408	Association Between Ambient Air Pollution and Amyloid Positron Emission Tomography Positivity in Older Adults With Cognitive Impairment. JAMA Neurology, 2021, 78, 197.	4.5	54
409	Cerebrospinal fluid biomarker profiling in corticobasal degeneration: Application of the AT(N) and other classification systems. Parkinsonism and Related Disorders, 2021, 82, 44-49.	1.1	13

#	Article	IF	Citations
410	Novel biomarkers in Alzheimerâ€™s disease using high resolution proteomics and metabolomics: miRNAS, proteins and metabolites. Critical Reviews in Clinical Laboratory Sciences, 2021, 58, 167-179.	2.7	9
411	Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease. Current Opinion in Neurology, 2021, 34, 266-274.	1.8	54
412	Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12131.	1.2	19
413	Development of molecular tools for diagnosis of Alzheimerâ€™s disease that are based on detection of amyloidogenic proteins. Prion, 2021, 15, 56-69.	0.9	12
414	Moving fluid biomarkers for Alzheimerâ€™s disease from research tools to routine clinical diagnostics. Molecular Neurodegeneration, 2021, 16, 10.	4.4	101
415	The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid Î² and tau. Alzheimer's and Dementia, 2021, 17, 1575-1582.	0.4	51
416	The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2140-2156.	3.3	83
417	The effect of electroconvulsive therapy on neuroinflammation, behavior and amyloid plaques in the 5xFAD mouse model of Alzheimerâ€™s disease. Scientific Reports, 2021, 11, 4910.	1.6	5
418	Temporal Correlation of CSF and Neuroimaging in the Amyloid-Tau-Neurodegeneration Model of Alzheimer Disease. Neurology, 2021, 97, e76-e87.	1.5	17
419	Use of Alzheimerâ€™s Disease Cerebrospinal Fluid Biomarkers in A Tertiary Care Memory Clinic. Canadian Journal of Neurological Sciences, 2022, 49, 203-209.	0.3	5
420	High-Sensitivity and Trace-Amount Specimen Electrochemical Sensors for Exploring the Levels of Î²-Amyloid in Human Blood and Tears. Analytical Chemistry, 2021, 93, 8099-8106.	3.2	19
421	Amyloid-type Protein Aggregation and Prion-like Properties of Amyloids. Chemical Reviews, 2021, 121, 8285-8307.	23.0	98
422	Critical Appraisal of Amyloid Lowering Agents in AD. Current Neurology and Neuroscience Reports, 2021, 21, 39.	2.0	57
423	Neurodegeneration, Alzheimer's disease biomarkers, and longitudinal verbal learning and memory performance in late middle age. Neurobiology of Aging, 2021, 102, 151-160.	1.5	6
424	Refining the amyloid Î² peptide and oligomer fingerprint ambiguities in Alzheimerâ€™s disease: Mass spectrometric molecular characterization in brain, cerebrospinal fluid, blood, and plasma. Journal of Neurochemistry, 2021, 159, 234-257.	2.1	8
425	Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy. Neurology, 2021, 97, .	1.5	50
426	Bias-generating factors in biofluid amyloid-Î² measurements for Alzheimerâ€™s disease diagnosis. Biomedical Engineering Letters, 2021, 11, 287-295.	2.1	6
427	Mass spectrometryâ€based methods for robust measurement of Alzheimer's disease biomarkers in biological fluids. Journal of Neurochemistry, 2021, 159, 211-233.	2.1	29

#	Article	IF	Citations
428	Are Parkinsonâ€™s Disease Patients the Ideal Preclinical Population for Alzheimerâ€™s Disease Therapeutics?. Journal of Personalized Medicine, 2021, 11, 834.	1.1	3
429	Different Sides of Depression in the Elderly: An In-depth View on the Role of AÎ² Peptides. Current Medicinal Chemistry, 2022, 29, 5731-5757.	1.2	7
430	Relationship between inferior frontal sulcal hyperintensities on brain MRI, ageing and cerebral small vessel disease. Neurobiology of Aging, 2021, 106, 130-138.	1.5	5
431	Diagnostic biomarkers in Alzheimerâ€™s disease. Biomarkers in Neuropsychiatry, 2021, 5, 100041.	0.7	12
432	Fluid biomarkers for Alzheimer's disease in Down syndrome: Current status and novel trends. , 2022, , 97-128.		0
433	Matching Clinical Diagnosis and Amyloid Biomarkers in Alzheimerâ€™s Disease and Frontotemporal Dementia. Journal of Personalized Medicine, 2021, 11, 47.	1.1	9
434	Multiple Diagnostic Tests Are Needed to Assess Multiple Causes of Dementia. Archives of Neurology, 2006, 63, 144.	4.9	14
435	Diagnostic Assessment in Primary Progressive Aphasia: An Illustrative Case Example. American Journal of Speech-Language Pathology, 2020, 29, 1833-1849.	0.9	7
437	Effects of apoE Deficiency and Occlusal Disharmony on Amyloid-Beta Production and Spatial Memory in Rats. PLoS ONE, 2013, 8, e74966.	1.1	14
439	Soluble Amyloid-β . Levels and Late-Life Depression. Current Pharmaceutical Design, 2014, 20, 2547-2554.	0.9	28
440	Rapid Improvement of Canine Cognitive Dysfunction with Immunotherapy designed for Alzheimer's Disease. Current Alzheimer Research, 2013, 10, 482-493.	0.7	17
443	CSF tau and Î²-amyloid as biomarkers for mild cognitive impairment. Dialogues in Clinical Neuroscience, 2004, 6, 379-390.	1.8	27
444	Biological markers for early detection and pharmacological treatment of Alzheimer's disease. Dialogues in Clinical Neuroscience, 2009, 11, 141-157.	1.8	39
447	Cerebrospinal fluid and blood biomarkers in Alzheimerâ€™s disease. World Journal of Psychiatry, 2011, 1, 8.	1.3	34
448	Increased plasma brain-derived neurotrophic factor (BDNF) as a potential biomarker for and compensatory mechanism in mild cognitive impairment: a case-control study. Aging, 2021, 13, 22666-22689.	1.4	11
449	The Amyloid _-Protein and Alzheimer's Disease. Frontiers in Neuroscience, 2012, , 1-85.	0.0	0
450	GÃ©nÃ©tique des formes autosomiques dominantes de maladie dâ€™Alzheimer. , 2013, , 157-174.		0
451	Biomarkers for Alzheimerâ€™s Disease: Imagination or Reality-View and Review!. Journal of Behavioral and Brain Science, 2013, 03, 393-402.	0.2	0

#	Article	IF	Citations
452	Impact of the IWG/Dubois Criteria for Alzheimerâ€™s Disease in Imaging Studies. , 2014, , 309-322.		0
453	Cerebrospinal Fluid Biomarkers in Alzheimerâ€™s Disease and Frontotemporal Dementia. , 2014, , 131-157.		0
454	AÎ² Imaging in Aging, Alzheimerâ€™s Disease and Other Neurodegenerative Conditions. , 2014, , 213-254.		2
455	Neuroradiologic Applications in the Assessment of Alzheimerâ€™s Disease and the Potential Implications of Brain Imaging in Forensic Psychiatry. Cureus, 2014, , .	0.2	0
457	New Frontiers in Alzheimer's Disease Diagnosis. , 0, , .		0
459	Clinical Meaningfulness of Biomarker Endpoints in Alzheimerâ€™s Disease Research. Neuromethods, 2018, , 235-248.	0.2	0
462	Ruolo dei biomarcatori nella diagnostica liquorale della malattia di Alzheimer. Rivista Italiana Della Medicina Di Laboratorio, 2019, 15, .	0.2	0
465	Cerebrospinal fluid and blood biomarkers in the diagnostic assays of Alzheimerâ€™s disease. Journal of Innovative Optical Health Sciences, 2022, 15, .	0.5	9
466	Neurodegenerative Disorders of Alzheimer, Parkinsonism, Amyotrophic Lateral Sclerosis and Multiple Sclerosis: An Early Diagnostic Approach for Precision Treatment. Metabolic Brain Disease, 2022, 37, 67-104.	1.4	24
469	Plasma Biomarkers Ascertained With Immunomagnetic Reduction Diagnosing Early-Stage Alzheimer's Disease: A Systematic Review. Innovations in Digital Health Diagnostics and Biomarkers, 2021, 1, 8-15.	0.5	1
470	Amyloid and Tau in Alzheimerâ€™s Disease: Biomarkers or Molecular Targets for Therapy? Are We Shooting the Messenger?. American Journal of Psychiatry, 2021, 178, 1014-1025.	4.0	11
471	Cerebrospinal fluid protein biomarkers for Alzheimerâ€™s disease. Neurotherapeutics, 2004, 1, 213-225.	2.1	0
472	AÎ² Imaging in Aging, Alzheimerâ€™s Disease, and Other Neurodegenerative Conditions. , 2021, , 283-343.		0
473	Impact of the New Conceptual Framework of Alzheimerâ€™s Disease in Imaging Studies. , 2021, , 427-451.		0
475	Development of a Low-Molecular-Weight AÎ²42 Detection System Using a Enzyme-Linked Peptide Assay. Biomolecules, 2021, 11, 1818.	1.8	5
476	Biomarkers used in Alzheimerâ€™s disease diagnosis, treatment, and prevention. Ageing Research Reviews, 2022, 74, 101544.	5.0	60
477	Associating Alzheimerâ€™s disease pathology with its cerebrospinal fluid biomarkers. Brain, 2022, 145, 4056-4064.	3.7	19
478	Biofluidâ€based biomarkers for Alzheimer's diseaseâ€“related pathologies: An update and synthesis of the literature. Alzheimer's and Dementia, 2022, 18, 1687-1693.	0.4	24

#	Article	IF	Citations
479	Biobanking and Biomarkers in the Alzheimerâ€™s Disease Drug-Development Ecosystem. , 2022, , 123-134.		0
480	Plasma AÎ² as a biomarker for predicting AÎ²-PET status in Alzheimerâ€™s diseaseï¼ša systematic review with meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 513-520.	0.9	10
481	Bloodâ€based biomarkers for Alzheimer's disease. EMBO Molecular Medicine, 2022, 14, e14408.	3.3	122
482	Impact of Anti-amyloid-Î² Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimerâ€™s Disease: A Focus on Aducanumab and Lecanemab. Frontiers in Aging Neuroscience, 2022, 14, 870517.	1.7	91
483	Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nature Reviews Neurology, 2022, 18, 400-418.	4.9	99
485	The Relationship Between Suboptimal Social Networks and Postoperative Delirium: The PNDABLE Study. Frontiers in Aging Neuroscience, 0, 14, .	1.7	1
486	Identification and validation of Alzheimerâ€™s disease-related metabolic brain pattern in biomarker confirmed Alzheimerâ€™s dementia patients. Scientific Reports, 2022, 12, .	1.6	13
487	Application of peptide biomarkers in life analysis based on liquid chromatographyâ€“mass spectrometry technology. BioFactors, 2022, 48, 725-743.	2.6	3
488	Apolipoprotein E Genotype e2: Neuroprotection and Its Limits. Frontiers in Aging Neuroscience, 0, 14, .	1.7	12
490	Blood-based AÎ²42 increases in the earliest pre-pathological stage before decreasing with progressive amyloid pathology in preclinical models and human subjects: opening new avenues for prevention. Acta Neuropathologica, 2022, 144, 489-508.	3.9	6
491	The Influence of Orthopedic Surgery on Circulating Metabolite Levels, and their Associations with the Incidence of Postoperative Delirium. Metabolites, 2022, 12, 616.	1.3	0
492	Preclinical Alzheimerâ€™s disease biomarkers accurately predict cognitive and neuropathological outcomes. Brain, 2022, 145, 4506-4518.	3.7	15
493	CSF biomarkers in patients with epilepsy in Alzheimerâ€™s disease: a nation-wide study. Brain Communications, 2022, 4, .	1.5	5
494	Proteomic Discovery and Validation of Novel Fluid Biomarkers for Improved Patient Selection and Prediction of Clinical Outcomes in Alzheimerâ€™s Disease Patient Cohorts. Proteomes, 2022, 10, 26.	1.7	9
495	Is liquid biopsy mature enough for the diagnosis of Alzheimerâ€™s disease?. Frontiers in Aging Neuroscience, 0, 14, .	1.7	9
496	Clinical utility of cerebrospinal fluid biomarkers in the evaluation of cognitive impairment: a systematic review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2023, 94, 113-120.	0.9	10
498	Fluid biomarkers in Alzheimer's disease. Advances in Clinical Chemistry, 2023, , 249-281.	1.8	7
499	PET molecular imaging for pathophysiological visualization in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 765-783.	3.3	18

#	Article	IF	Citations
500	Direct coupling of fiber-in-tube solid-phase microextraction with tandem mass spectrometry to determine amyloid beta peptides as biomarkers for Alzheimer's disease in cerebrospinal fluid samples. Talanta, 2023, 254, 124186.	2.9	5
501	Predicting AT(N) pathologies in Alzheimerâ€™s disease from blood-based proteomic data using neural networks. Frontiers in Aging Neuroscience, 0, 14, .	1.7	5
502	PICALM rs3851179 Variants Modulate Left Postcentral Cortex Thickness, CSF Amyloid Î²42, and Phosphorylated Tau in the Elderly. Brain Sciences, 2022, 12, 1681.	1.1	2
503	Salivary Aβ1â€“42 may be a quick-tested biomarker for clinical use in Alzheimerâ€™s disease: a meta-analysis. Journal of Neurology, 2023, 270, 1945-1954.	1.8	5
504	Language patterns in Japanese patients with Alzheimer disease: A machine learning approach. Psychiatry and Clinical Neurosciences, 2023, 77, 273-281.	1.0	0
505	Neuropathologyâ€based APOE genetic risk score better quantifies Alzheimer's risk. Alzheimer's and Dementia, 2023, 19, 3406-3416.	0.4	2
507	Contribution of clinical information to the predictive performance of plasma Î²-amyloid levels for amyloid positron emission tomography positivity. Frontiers in Aging Neuroscience, 0, 15, .	1.7	1
508	Diagnostic Biomarkers of Amyloid and Tau Pathology in Alzheimerâ€™s Disease: An Overview of Tests for Clinical Practice in the United States and Europe. journal of prevention of Alzheimer's disease, The, 0, , .	1.5	2
509	Differential involvement of hippocampal subfields in the relationship between Alzheimer's pathology and memory interference in older adults. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2023, 15, .	1.2	1
510	Distinct CSF biomarker-associated DNA methylation in Alzheimerâ€™s disease and cognitively normal subjects. Alzheimer's Research and Therapy, 2023, 15, .	3.0	4
511	Biomarkers of Alzheimerâ€™s disease: Past, present and future clinical use. Biomarkers in Neuropsychiatry, 2023, 8, 100063.	0.7	3
512	Small-molecule theranostics in Alzheimer's disease. European Journal of Medicinal Chemistry, 2023, 255, 115382.	2.6	9
527	Shifting Paradigm in Early Detection and Prediction of Alzheimer's Disease. Advances in Medical Technologies and Clinical Practice Book Series, 2024, , 279-304.	0.3	0